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Abstract
A series of potent amide non-urea inhibitors of soluble epoxide hydrolase (sEH) is disclosed. The
inhibition of soluble epoxide hydrolase leads to elevated levels of epoxyeicosatrienoic acids
(EETs), and thus inhibitors of sEH represent one of a novel approach to the development of
vasodilatory and anti-inflammatory drugs. Structure-activities studies guided optimization of a
lead compound, identified through high-throughput screening, gave rise to sub-nanomolar
inhibitors of human sEH with stability in human liver microsomal assay suitable for preclinical
development.
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Soluble epoxide hydrolase (sEH) is a bifunctional homodimeric enzyme with hydrolase and
phosphatase activity detected in various species ranging from plants to mammals.1 In
humans it is mostly located in liver, kidney, intestinal and vascular tissues.2 The sEH
enzyme is selective for aliphatic epoxides of fatty acids, and one of the most important
substrates is epoxyeicosatrienoic acid (EET).3 EETs are one of the metabolic derivatives of
arachidonic acid.4 The epoxygenase CYP2 enzymes catalyse the epoxydation of olefin
bonds of arachidonic acid generating EETs.5 EETs exhibit vasodilatory effects in various
arteries6,7 and possess anti-inflammatory properties.8 sEH mediates the addition of water to
EETs, converting them to the corresponding diols – dihydroxyeicosatrienoic acids (DHETs),
which show abolished or diminished biological activity . The inhibition of this enzyme,
therefore may represent a promising therapeutic strategy since it would lead to elevated
levels of EETs, which could then have beneficial therapeutic effects on blood pressure and
inflammation.9
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The most explored sEH inhibitors to date are urea-based compounds and numerous
structure-activity relationship (SAR) studies led to discovery of several potent urea-based
sEH inhibitors with IC50s in the lower nanomolar range.10,11 However, the urea-based
inhibitors often suffer from poor solubility and stability, which hinders their
pharmacological use in vivo.12,13
Amides, carbamates and thioureas have been evaluated as alternative pharmacophores in an
attempt to improve physical properties of urea-based inhibitors.10,11 In this report we
disclose our efforts towards designing novel non-urea, amide-based inhibitors of sEH.
Previously we identified through high-throughput screening (HTS)14 several hits with a low
micromolar to low nanomolar potency. A majority of these compounds were urea-based
inhibitors. However, several were non-ureas and among them the most potent was the
derivative of isonipecotic acid, with substantial activity of 20 nM. Our initial SAR studies15
led to discovery of compound 1 with an IC50 of 7.9 nM (Figure 1). Based on its potent
inhibition of sEH activity, we continued our evaluation of the right-hand side (2,4,6-
trimethylphenyl ring) of 1, and this follow-up SAR study revealed compound 2, with an
IC50 of 1.6 nM.16
Herein we report modifications of the left-hand side of non-urea inhibitor 2. In particular,
we were focused on the replacement of the cycloheptyl moiety of the 2, following the SAR
reported by Rose et al.17, and guided by docking model of the previously reported protein-
inhibitor complex and X-ray cocrystal structure of human sEH and 1.
The X-ray crystallographic structure of human sEH and an inhibitor 4-(3-cyclohexylureido)-
carboxylic acid complex (PDB code: 1ZD3) revealed the catalytic pocket and key structural
features required to inhibit sEH enzyme. Two tyrosine (Tyr383 and Tyr466) and one
aspartic acid (Asp335) residues, located in the hydrolase catalytic pocket of sEH, are
involved in degradation of EET - tyrosine residues act as hydrogen bond donors to promote
the epoxide ring opening by Asp335.18,19 The urea group of 4-(3-cyclohexylureido)-
carboxylic acid fits in the hydrolase catalytic pocket and the carbonyl oxygen of the urea
moiety is engaged in a hydrogen bond interaction with Tyr381 and Tyr466 while the N–H
acts as a hydrogen bond donor to Asp335 The co-crystal structure of 1 and human sEH was
determined (See Supplementary info) to guide the design of more potent inhibitors. Our
close examination of the structure revealed that the amide moiety of 1 is positioned in the
same fashion as the urea group in urea-based inhibitors, where the amide moiety, instead of
urea group, is involved in hydrogen bonding with tyrosine and aspartic acid residues in the
catalytic pocket of sEH. We noticed that the 2,4,6-trimethylphenyl ring on the right-hand
side of this inhibitor occupies the smaller of the two lipophilic pockets in the sEH active site,
while the cycloheptyl moiety on the left-hand side is directed towards the large deep pocket
that opens toward solvent, which allows access for further structural modifications (Figure
2). We therefore hypothesized that the left-hand segment in 1 could be optimized to further
improve the potency of this group of non-urea sEH inhibitors.
Scheme 1 outlines the synthetic route used to form the left-hand side library of non-urea
amide sEH inhibitors. Sulfonamide 5 was prepared from two commercially available
starting materials, methyl isonipecotate 3 and 2,4-dimethylbenzenesulfonyl chloride 4.
Saponification of this methyl ester with LiOH afforded acid 6. EDC peptide coupling
reactions of 6 with various commercially available amines provided analogs 7-1 to 7-46.
A sensitive fluorescent based assay was employed to determine IC50 values of these sEH
inhibitors. In short, cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxyran-2-yl)
methyl carbonate (CMNPC) was used as the fluorescent substrate. Human sEH (1 nM) was
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incubated with the inhibitor for 5 min in pH 7.0 Bis–Tris/HCl buffer (25 mM) containing 0.1
mg/mL of BSA at 30 °C prior to substrate introduction ([S] = 5 μM). Activity was
determined by monitoring the appearance of 6-methoxy-2-naphthaldehyde over 10 min by
fluorescence detection with an excitation wavelength of 330 nm and an emission wavelength
of 465 nm. Reported IC50 values are the average of the three replicates with at least two
datum points above and at least two below the IC50.20 In Table 1 are summarized the
biological results.
Previous studies on urea-based inhibitors containing piperidine moiety have shown that the
hydrophobic cycloalkyl groups on the left-hand side of the molecules are positively
correlated with inhibitory potency.17 Among this set of analogs we identified several
inhibitors possessing improved or similar potency comparing to the lead compound 2,
specifically compound 7-10 showed an IC50 of 0.4 nM, the most potent amide non-urea sEH
inhibitor reported to date. Replacement of cycloalkyl ring with a more compact phenyl ring
(compound 7-12), resulted in 15-fold drop in potency against the human sEH. However,
introduction of the phenyl ring allowed us access to electronically and sterically diverse
structures, and as well attachment of various polar groups, which could in turn improve
physical and pharmacokinetic properties. Placement of fluorine or bromine in the ortho
position did not significantly change the potency of the non-urea inhibitors (7-13 and 7-15),
while chlorine and methyl group decreased the potency for 10 and 30-fold, respectively
(7-14 and 7-16).
Polar hydroxyl group in ortho position showed clear negative effect on potency in non-urea
based compounds (7-17). Although the para substitution is generally tolerated, placement of
polar substituents resulted in less potent inhibitors.
Placement of methoxy group in para position (compound 7-18) did not significantly changed
the potency comparing to compound 7-12, while introduction of hydroxyl group in the same
position (compound 7-19 can be observed as a metabolite of 7-18) led to 2-fold decreased
potency presumably because of unfavorable electron character and increased polarity.
Similar results, but with more drastically change in potency can be observed based on results
for methyl ester compound 7-21 and its corresponding carboxylic acid compound 7-22. We
synthesized the 4-trifluoromethoxyphenyl analog 7-23, since it has been reported previously
that this moiety is more metabolically stable replacement for cycloalkyl rings.12 We
observed 4-fold increase in potency for this compound compared with compound 7-12, thus
it was selected for further pharmacokinetic studies. Interestingly, the analog 7-24, showed 5-
fold increased activity comparing to phenyl compound 7-12, despite the presence of the high
polarity nitro functionality. The metabolic stability for this inhibitor was evaluated as well.
We also introduced a basic nitrogen (piperidine and morpholine rings in para position;
analogs 7-25, 7-26 and 7-27) in order to allow formulation of the inhibitor as a salt. These
modifications did not improve the potency, similar to other polar substituents in this
position. On the other hand, the inhibition potencies increased when small non-polar para or
meta substituents were added (7-28, 7-29, 7-30 and 7-31). Since it has been known that
halogens can enhance polarity and decrease the rate of metabolism degradation due to their
electron withdrawing effect on the aromatic ring, we decided to prepare a set of analogs
containing various halogens in different position on the left-hand side phenyl moiety. The
fluorinated, chlorinated and brominated para-phenyl compounds (7-32, 7-33 and 7-34,
respectively) did not show significant improvement in activity compared to compound 7-12.
Placement of two chlorine atoms in meta, and meta and para positions showed a 2-fold and
3-fold lower IC50 against human sEH enzyme, 7-35 and 7-37 respectively.
Future rational optimization of these meta, para disubstituted halogens might yield
additional more potent compounds. Inclusion of 2-naphthalene on the left side of the
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molecule 7-38 resulted in high potency against the human enzyme, which is already shown
in recent literature17, thus, we decided to test in vitro metabolic profile for this compound.
We tried to introduce a nitrogen in this moiety in order to improve physical properties and
the ease of formulation. Various aminoquinolines were attached via different position to
central non-urea moiety. 5-Aminoquinoline derivative 7-39 led to 5-fold lower potency
against sEH, 3-aminoquinoline derivative 7-40 showed 30-fold diminished potency, while 6-
and 8-aminoquinoline analogs 7-41 and 7-42, led to even more drastically decreased
potency, 50-fold and 180-fold, respectively. The poor performance of aminoquinolines
returned our attention to 2-naphthalene moiety, where we tried to introduce polar group in
position 6. Methylester analog 7-43 showed slight decrease in activity, while corresponding
carboxylic acid 7-44 had 15-folds lower inhibition then the 2-naphthalene analog.
Interestingly, 3,4-methylenedioxybenzene analog 7-45 led us to discovery of subnano molar
potent inhibitor of human sEH enzyme.
The selected non-urea sEH inhibitors were profiled in human liver microsomal assay22 as a
predictor of in vivo oxidative metabolism (Table 2). Our results from this assay indicated
that although compounds with hydrophobic cycloalkyl substituents on the right-side of the
non-urea piperidine scaffold such as cyclohexyl, methylcyclohexyl, cycloheptyl, cyclooctyl
or adamantyl were more potent inhibitors of sEH, compared to compounds with aromatic
moiety, these compounds showed poor metabolic profile in human liver microsomal assay.
Evaluation of the in vitro metabolic stability for aromatic compounds revealed intermediate
metabolic profiles for compounds with para-substitution (compounds 7-23 and 7-24), with
the exception of the carboxylic acid derivative 7-44, which demonstrated excellent in vitro
metabolic stability in human liver microsomes.
In summary, our structure-activity relationship of the lead 2 reveals some particular
structural requirements to the left-hand side part of the piperidine amide-based sEH
inhibitors. A varying degree of bulky, nonpolar cycloalkyl rings are well tolerated in this
region by target enzyme. In contrast, proper substitution on the phenyl ring is crucial for
attaining good potency, emphasizing the importance of the small nonpolar groups and
halogens in para position as a recognition element for sEH, suggesting that left-hand side
phenyl is in a relatively close proximity to a several hydrophobic residues located in the
large, non-polar pocket of sEH that opens towards solvent, and probably participating in a
π-stacking interaction with them. The above observations are corroborated by the
costructure of 1 with sEH.
While low nanomolar and sub-nanomolar potencies were achieved, the majority of tested
inhibitors in this non-urea based series were still not as stable in human liver microsome
assay as some other non-urea sEH inhibitors previously reported.21 However, compound
7-4423 showed good stability and it will be further explored in various in vivo experiments.
Our future work will focus as well on possible combinations of these data obtained from this
SAR study and combinations of related fragments that would be used for future design of
highly potent inhibitors with improved pharmacokinetic profiles.
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MS (M-+H): 465.
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Chemical structures of non-urea inhibitors
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The active site of the hydrolase domain of human sEH complexed with 1. The Fo-Fc electron
density map is contoured at 3σ. Hydrogen bonds are indicated by dashes. The structure
reveals that the 2,4,6-trimethylphenyl group is directed into the hydrophobic environment,
whereas the cycloheptyl moiety is exposed toward the solvent. Coordinates of the complex
deposited as 4HAI with the Protein Data Bank. The image was produced using PYMOL.
Pecic et al. Page 8














Reagents and conditions: (a) Et3,N, CH2Cl2, rt, 24 h; 89% (b) LiOH, THF/H2O, rt, 24 h;
91% (c) R-NH2, EDC, DMAP, CH2C12, rt, 24 h; 65-92%.
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